A Phase 1 interventional study of Nifedipine/Candesartan (BAY 98-7106) and Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333) in Hypertension, Essential, sponsored by Bayer. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-10.
Sponsored by Bayer · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Essential Hypertension with a site in Germany — 1 open to participants now, 3 under way, none of them phase 3. Essential Hypertension · Germany.
Among the 35 studies in Essential Hypertension with a site in Germany, this one is the 33rd largest by enrollment, is one of 2 that started in 2011, is one of 2 in phase 1, and was the 26th registered.
481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.
Browse Essential Hypertension studies →1 of the 35 studies in Essential Hypertension with a site in Germany is open now. Recruiting first, the newest first:
Orchestra BioMed, Inc · Sites in Germany, United States, Australia and 12 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 24 · Phase 4 2
First in 2001; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 429 across the 35 interventional studies. Of the 31 that completed or were terminated, 15 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 35 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 9 studies filed under Essential Hypertension — fewer than ten, so there is no comparison to draw.
1 of the studies in Essential Hypertension with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Essential Hypertension with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized, open label, single dose, 2-way crossover study to investigate the bioequivalence of a new fixed dose combination (FDC) tablet of nifedipine GITS and candesartan with the corresponding loose combination under fed conditions.
Clinical pharmacology
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of medication within 4 weeks prior to the first study drug administration which could interfere with the products (e.g. inhibitors or CYP3A inducers)
At the first screening visit
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nifedipine/Candesartan (BAY 98-7106)
Drug: Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)
Drug pages: Nifedipine · Candesartan
Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
Drug pages: Nifedipine · Candesartan
Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
Cmax
Maximum drug concentration in plasma after dose administration for nifedipine and candesartan
Time frame: within 48 hours after each dosing
AUC(0-tlast)
Area under the drug-concentration vs. time curve from time 0 to the last data point for nifedipine and candesartan
Time frame: within 48 hours after each dosing
AUC
Area under the curve from time 0 to infinity after single dose for nifedipine and candesartan
Time frame: Within 48 hours after each dosing
Cmax,norm
Dose normalized Cmax for nifedipine and candesartan
Time frame: Within 48 hours after each dosing
AUCnorm
AUC normalized for dose and body weight for nifedipine and candesartan
Time frame: Within 48 hours after each dosing
AUC(0-48)
Area under the plasma concentration-time curve from time zero to 48h for nifedipine and candesartan
Time frame: Within 48 hours after each dosing
Tmax
The time of the maximum concentration for nifedipine and candesartan
Time frame: Within 48 hours after each dosing
t1/2
Half-life for nifedipine and candesartan
Time frame: Within 48 hours after each dosing
MRT
The mean residence time for nifedipine and candesartan
Time frame: Within 48 hours after each dosing
CL/F
Oral plasma clearances for nifedipine and candesartan
Time frame: Within 48 hours after each dosing
Number of participants with adverse events
Time frame: Approximately 3-7 weeks per subject
The record gives a start of Apr 2011, a primary completion of Aug 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nifedipine · Candesartan